

**CHARACTERISATION OF NOVEL MATRIX-BINDING
INTERACTIONS FOR LATENT TRANSFORMING GROWTH
FACTOR- β -BINDING PROTEIN-2 (LTBP-2), WITH EMPHASIS
ON HEPARIN AND HEPARAN SULPHATE PROTEOGLYCANS**

Mahroo Parsi

**Discipline of Pathology
School of Medical Sciences, The University of
Adelaide, Australia**



**A thesis submitted for the degree of Doctor of Philosophy (PhD) in July, 2010
with permission from the Faculty of Health Sciences, the University of Adelaide**

DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Mahroo Parsi

July 2010

SUPERVISORS:

Dr. Mark A. Gibson
Dr. Christopher Bagley
Dr. Eric Hanssen

ACKNOWLEDGEMENTS

Early in this project, it became very clear to me that I could not have completed this journey alone. Although the list of people I wish to thank extends beyond the limits of this format, I would like to thank the following persons for their dedication, advice and support.

My Primary supervisor, Dr. Mark Gibson, you have been a significant presence in my life. My achievements over the last five years have been all because of your many helpful suggestions, important advice and constant encouragement. There are no words to express my gratitude, except to say I am forever grateful for your wisdom, knowledge and also believing in me. I hope to make you proud one day.

I also wish to express my appreciation to Dr. Chris Bagley for always being available and supplying me with resources to carryout some of the proteomic techniques. Also further thanks for the many valuable suggestions and constructive advice.

Special thanks to Dr. Julian Adams for reading my thesis over and over again and the many valuable suggestions that indeed help improve the quality of this thesis. Also for all the random conversations during the short period of time we worked together.

My keen appreciation goes to the staff of the Discipline of pathology and Adelaide Microscopy at University of Adelaide for their valuable assistance and technical support.

To my family, mom, dad and Golroo and also dearest friends, all I can say is it would take another thesis to express my deep love for you. Your patience, love and encouragement have upheld me, particularly in those many months in which I spent all my time with my computer than with you. I will make it up to each and everyone of you.

TABLE OF CONTENTS

ABBREVIATIONS	viii
LIST OF FIGURES	x
LIST OF TABLES	xii
SUMMARY	xiii

CHAPTER 1

INTRODUCTION	1
1.1 Extracellular Matrix	1
1.1.1 Collagens	1
1.1.2 Elastin and Elastic fibres.....	2
1.1.3 Proteoglycans.....	5
1.1.3.1 Perlecan.....	7
1.1.3.2 Syndecans	9
1.1.4 Glycoproteins.....	111
1.2 Microfibrillar structures of the matrix	12
1.2.1 Collagen VI microfibrils	12
1.2.1.1 Collagen VI.....	12
1.2.1.1.1 Structure.....	12
1.2.1.1.2 Function and distribution of Collagen VI.....	14
1.2.1.1.3 Interaction of collagen VI with other matrix components.....	16
1.2.1.1.4 Heritable disorders of collagen VI.....	17
1.2.1.2 Transforming growth factor- β -inducible gene-h3 (β ig-h3)	18
1.2.1.2.1 Structure of β ig-h3	19
1.2.1.2.2 Possible function of β ig-h3 and its interaction with other matrix proteins.....	19
1.2.1.2.3 Expression and tissue distribution of β ig-h3.....	21
1.2.1.2.4 Diseases associated with β ig-h3	21
1.2.2 Fibrillin-microfibrils	22
1.2.2.1 Fibrillins.....	23
1.2.2.1.1 Structure of fibrillins.....	23
1.2.2.1.2 Tissue distribution of Fibrillins.....	24
1.2.2.1.3 Functions of fibrillins.....	25
1.2.2.1.4 Interaction of fibrillins with other matrix components.....	26
1.2.2.1.5 Congenital disorders related to fibrillins	29
1.2.2.2 Latent transforming growth factor- β binding proteins	30
1.2.2.2.1 Structure and function of LTBP-1.....	31
1.2.2.2.2 Tissue distribution of LTBP-2	34
1.2.2.2.3 Possible function of LTBP-2	35
1.2.2.2.4 Diseases associated with the LTBP-2.....	36
Aims of the present study	37

CHAPTER 2

MATERIALS AND METHODS	39
2.1 General molecular biology protocols	39
2.1.1 Polymerase Chain Reaction (PCR).....	39

2.1.2 DNA Purification by Agarose Gel Electrophoresis	39
2.1.3 “A”-tailing and Ligation	40
2.1.4 Transformation of Competent Cells	40
2.1.5 Restriction digests	41
2.1.6 DNA Sequence Analysis	41
2.1.7 Dephosphorylation	42
2.2 Production of human LTBP-2 fragments	42
2.2.1 LTBP-2C(H)	42
2.2.2 LTBP-2NT(H)	43
2.3 Expression of recombinant LTBP-2C(H)	44
2.4 Purification of recombinant full length LTBL-2, βig-h3 and LTBP-2C(H)	
fragment	45
2.5 Freezing and Thawing of recombinant protein expressing cells	47
2.6 SDS-PAGE coomassie blue staining and western immunoblotting	47
2.7 Silver staining	49
2.8 Determining the molecular weight of unknown proteins	49
2.9 Mass spectrometric analysis	50
2.10 Synthesis and Fractionation of Covalently bound conjugates of heparin and	
albumin	51
2.11 Uronic acid assay	52
2.12 Determination of protein concentration using Bradford assay	52
2.13 Solid phase binding assay	53
2.13.1 Detecting interaction between two proteins	53
2.13.2 Saturation binding curve	53
2.13.3 Inhibition of binding	54
2.13.4 Determination of dissociation constants	54
2.13.5 Statistical analysis	55
2.13.6 Digestion of glycosaminoglycans (GAGs)	55
2.14 Tissue sectioning and immunofluorescence	55
2.15 Coupling of rβig-h3 and rLTBP-2 to Cyanogen Bromide (CNBr)-activated	
Sepharose 4B	56
2.16 Using nickel chelate chromatography for identification of binding partners	
of rβig-h3	56
2.17 Two-Dimension Gel Electrophoresis (2-DGE)	57
2.18 Difference Gel Electrophoresis (DIGE) using CyDye DIGE Fluor Dyes	57

CHAPTER 3

BINDING INTERACTION OF HUMAN LTBP-2 WITH HEPARIN/HEPARAN SULPHATE PROTEOGLYCANS

3.1 Expression and purification of human recombinant LTBP-2	59
3.2 Synthesis and purification of Heparin-Albumin Conjugate	61
3.3 The analysis of LTBP-2 interaction with heparin	61
3.3.1 Solid phase immuno-assays	61
3.3.2 LTBP-2 interacts with heparin-albumin conjugate (HAC)	65
3.3.3 The interaction of LTBP-2 with heparin is not a non-specific interaction with	
polyanionic GAG	68
3.3.4 LTBP-2 interaction with heparin depends on calcium or other divalent cations	68
3.3.5 Kinetic analysis of the interaction between LTBP-2 and heparin	70

CHAPTER 4

THE CENTRAL REGION OF LTBP-2 CONTAINS A BINDING SITE FOR HEPARIN 72

4.1 Expression, purification and characterisation of the central region of LTBP-2 (LTBP-2C(H)).....	72
4.1.1 Expression and purification of LTBP-2C(H).....	72
4.1.2 Analysis and authentication of rLTBP-2C(H).....	73
4.1.3 Peptide mass finger-printing of rLTBP-2C(H).....	74
4.2 The central region of LTBP-2 contains a binding site for heparin	75
4.2.1 Defining the affinity between central region of LTBP-2 and heparin	76

CHAPTER 5

LTBP-2 INTERACTIONS WITH PERLECAN AND SYNDECANS. 79

5.1 LTBP-2 interacts with Perlecan	79
5.2 The interaction of LTBP-2 with perlecan is via the heparan sulphate side chains ...	81
5.3 The interaction of LTBP-2 with perlecan is cation dependent.....	83
5.4 LTBP-2 interacts with syndecan-4 but not syndecan-2.....	83

CHAPTER 6

IMMUNOHISTOCHEMICAL ANALYSIS OF HUMAN FOETAL AORTA INDICATES LTBP-2 HAS AREAS OF COLOCALISATION WITH PERLECAN.....86

6.1 Localisation of LTBP-2 on microfibrils and perlecan on basement membrane in human foetal aorta	86
6.1.1 LTBP-2 localises on fibrillin-1-microfibrils in the human foetal aorta.....	86
6.1.2 Perlecan is predominantly associated with smooth muscle BM in foetal aorta.....	89
6.1.3 Colocalisation of fibrillin-1 with perlecan.....	90
6.1.4 Colocalisation of LTBP-2 and perlecan in the foetal aorta	92

CHAPTER 7

IDENTIFICATION OF MATRIX MOLECULAR BINDING PARTNERS OF β ig-h3 AND LTBP-2 USING AFFINITY BINDING AND PROTEOMICS TECHNIQUES..... 94

7.1 Expression and purification of recombinant βig-h3	95
7.2 Preparation of the affinity column; coupling of rβig-h3 and rLTBP-2 to CNBr-activated sepharose-4B	96
7.3 Selection of tissue extracts for identification of binding partners for rβig-h3 and rLTBP-2	97
7.4 The use of BNLPMs-1M NaCl for identification of novel binding partners	99
7.4.1 Selecting a suitable binding buffer	99
7.4.2 Incubation of BNLPM with a sepharose column for detection of non-specific interactions.....	100
7.5 Identification of potential binding partners for rβig-h3 from the BNLPM-1M NaCl	102
7.5.1 Analysis of the binding proteins using Coomassie Blue staining.....	102
7.5.2 Detection of β ig-h3 in proteins eluted from r β ig-h3-sepharose.....	103
7.5.3 Detection of the potential binding proteins for r β ig-h3 using silver staining.....	105

7.5.4 Isolation of potential binding partners of β ig-h3 using immobilised-Metal Affinity chromatography	107
7.6 Identification of binding partners for rLTBP-2 from BNLPM using silver staining	111
7.7 Isolation of binding partners for rLTBP-2 from a basement membrane-rich mixture	112
7.8 Affinity chromatography improvements for isolation of binding ligands for βig-h3 and LTBP-2 from BNLPM.....	113
7.8.1 Dilution of BNLPM.....	113
7.8.2 Reducing the size of the ‘bait’ protein columns	114
7.9 Separation of proteins eluted from rβig-h3- and rLTBP-2- sepharose by 2-D Gel Electrophoresis (2-DGE)	116
7.9.1 Silver staining detection of proteins separated by 2-DGE.....	116
7.9.2 Improving the resolution of 2-DGE.....	118
7.9.3 Detection of proteins separated by 2-DGE using 2-D-DIGE technology	122
7.9.3.1 Labelling of the proteins with CyDye DIGE Fluor minimal dye	122
7.9.3.2 Labelling of the proteins with CyDye DIGE Fluor saturation dyes	126
 CHAPTER 8	
DISCUSSION AND FUTURE DIRECTIONS.....	128
8.1 Discussion	130
8.2 Future Directions	137
8.2.1 Experiments for the comprehensive understanding of LTBP-2 interactions with HSPG	137
8.2.2 Possible alternatives for the identification of binding partners for β ig-h3 and LTBP-2.....	138
 APPENDIX A.....	
APPENDIX B.....	141
APPENDIX C.....	144
REFERENCES.....	146

PRESENTATIONS AND PUBLICATION ARISING

Conference presentations and published abstracts

- 2007- Pan Pacific Connective Tissue Societies Symposium with Matrix Biology Society of Australia and New Zealand (MBSANZ) annual scientific meeting (Cairns, Australia)
Mahroo Parsi, John Whitelock and Mark A. Gibson
Interaction of Latent Transforming Growth factor –beta- Binding Protein-2 (LTBP-2) with heparin and heparan sulphate proteoglycan, Perlecan
- 2007- Gordon Research Conference for Elastin and Elastic Fibres (Massachusetts, USA)
Mahroo Parsi and Mark A. Gibson
Latent Transforming Growth factor-beta-Binding Protein-2 (LTBP-2) Interaction with heparin and heparan sulfate proteoglycans
- 2006- National Health and Medical Research Council, (Melbourne, Australia)
Mahroo Parsi and Mark A. Gibson
Identifying matrix binding partners of LTBP-2 and beta-igh3 using Fluorescence 2D Difference Gel electrophoresis (DIGE) method
- 2006- National Health and Medical Research Council, (Melbourne, Australia)
Mahroo Parsi and Mark A. Gibson
Interaction of Latent Transforming Growth factor –beta- Binding Protein-2 (LTBP-2) with heparin and heparan sulphate proteoglycans
- 2005- Matrix Biology Society of Australia and New Zealand (MBSANZ) annual scientific meeting, (Victor Harbor, Australia)
Mahroo Parsi, Eric Hanssen and Mark A. Gibson
Identification of Matrix Binding Proteins for Transforming Growth factor-beta-Inducible Gene-h3 (beta-igh3)

PUBLICATION

- Mahroo Parsi, Julian Adams and Mark A. Gibson**
LTBP-2 has multiple heparin/heparan sulphate binding sites. Matrix Biol 2010 Apr 9[Epub ahead of print].

AWARDS ARISING FROM PhD CANDIDATURE

2007- **Postgraduate travelling fellowship**
(The University of Adelaide)

2006 - **Research abroad scholarship**
(The University of Adelaide)

2005-2007- **Australian Postgraduate Award,**
University of Adelaide Scholarship

ABBREVIATIONS

Δ	heat deactivated
2-DGE-	Two-Dimension Gel Electrophoresis
2D DIGE-	2D difference Gel Electrophoresis
8-cys-	8-cysteine
A₂₆₀-	absorbance at 260 nm
A₄₅₀-	absorbance at 450 nm
A₅₂₀-	absorbance at 520 nm
A₅₉₅-	absorbance at 595 nm
βig-h3-	transforming growth factor-β-inducible gene-h3
BM-	basement membrane
BMP-	bone morphogenetic protein
BNLPMs-6M GuHCl-	Bovine nuchal ligament protein mixtures extracted with 6M GuHCl
BNLPMs-1M NaCl-	Bovine nuchal ligament protein mixtures extracted with 1M NaCl
BNLPs-	Bovine nuchal ligament proteins
bp-	base pairs
BSA-	bovine serum albumin
c-	complementary
C-6-S-	chondroitin-6-sulphate
cbEGF-	calcium binding epidermal growth factor
CCA-	congenital contractural arachnodactyly
CNBr-	cyanogen bromide
CoIP-	co-immunoprecipitation
Col-	column
CS-	chondroitin sulphate
ddH₂O-	double distilled water
DEAE-	Diethylaminoethyl
DIGE-	Difference Gel Electrophoresis
DMEM-	Dulbecco's Modification of Eagles Medium
E-	embryonic day
EBP-	elastin binding protein
ECM-	extracellular matrix
EDTA-	ethylene diamine tetraacetic acid
EGTA-	ethylene glycol tetraacetic acid
ELISA-	enzyme-linked immuno-sorbent assay
FCS-	foetal calf serum
g-	gravity
GAG-	glycosaminoglycan
GuHCl-	Guanidine hydrochloride
HAC-	heparin-albumin conjugates
HEK-	human embryo kidney
his₆-	6-histidine
HS-	heparan sulphate
HSPGs-	heparan sulphate proteoglycans
IgG-	Immunoglobulin G
K_d-	dissociation constant
kDa-	kiloDalton
LDL-	low-density lipoprotein
LTBP-	latent transforming growth factor-β binding protein
LTBP-2C(H)-	LTBP-2 C-terminal

LTBP-2NT(H)-	LTBP-2 N-terminal
μA-	microampere
μl-	microliter
M-	molar
MAGP-	microfibrillar-associated glycoprotein
MALDI-TOF-MS-	Matrix-assisted laser-desorption/ionisation time-of-flight mass spectrometry
min-	minutes
mM-	millimolar
NEAA-	non-essential amino acids
ng-	nanogram
Ni-	nickel
PCR-	polymerase chain reactions
PG-	proteoglycan
PVDF-	polyvinylidene difluoride
r-	recombinant
R_f -	relative mobility
RGD-	Arg-Gly-Asp
RT-	room temperature
SDS-PAGE-	sodium sulphate polyacrylamide gel electrophoresis
TBS	tris buffered saline
TGF-β-	transforming growth factor-β
UCMD-	Ullrich Congenital Muscular Dystrophy
V-	volts
v or vol-	volume
w-	weight

LIST OF FIGURES

Figure 1.1	Structure of glycosaminoglycans (GAGs) and proteoglycans (PGs).....	5
Figure 1.2	Schematic molecular structure of human perlecan.....	8
Figure 1.3	Cell surface HSPGs syndecans.....	10
Figure 1.4	Domain organisation and assembly of the alpha chains from collagen VI	13
Figure 1.5	Model for supramolecular assembly in the ECM of connective tissue	16
Figure 1.6	Schematic diagram of the domain structure of β ig-h3 molecule.....	19
Figure 1.7	Schematic representation of the three fibrillins.....	24
Figure 1.8	The schematic illustration of the binding sites of various ECM components on fibrillin-1.	27
Figure 1.9	Schematic representation of human LTBP-1-4.....	31
Figure 3.1	Schematic representation of rLTBP-2 and rLTBP-2 fragments.....	59
Figure 3.2	Optimisation of expression and purification of rLTBP-2	62
Figure 3.3	Fractionation of un-conjugated albumin and heparin-albumin conjugate (HAC) on DEAE sepharose C14B	62
Figure 3.4	Optimisation of the conditions for solid phase assays	64
Figure 3.5	Reducing non-specific interaction of LTBP-2 with the addition of carrier protein in solution.....	64
Figure 3.6	Saturation binding curve of the interaction of LTBP-2 and heparin.....	66
Figure 3.7	Inhibition binding curve of LTBP-2 interaction with heparin	67
Figure 3.8	Interaction of LTBP-2 with heparin is specific and is not a non-specific charge-related interaction	69
Figure 3.9	The interaction of LTBP-2 with heparin is cation dependent	69
Figure 3.10	Kinetic analysis of the interaction between LTBP-2 and heparin using solid phase binding assay	71
Figure 4.1	PCR amplification of a cDNA encoding rLTBP-2C(H) and analysis of purified recombinant protein.....	74
Figure 4.2	Heparin binds specifically to rLTBP-2C(H)	77
Figure 4.3	Kinetic analysis of the interaction between central fragment of LTBP-2 and heparin using solid phase binding assay.....	78

Figure 5.1	LTBP-2 interacts specifically with perlecan	80
Figure 5.2	Perlecan interacts with LTBP-2 via its HS-side chains.....	82
Figure 5.3	Preparation of the perlecan core protein.....	82
Figure 5.4	The interaction of perlecan with LTBP-2 is cation dependent.....	85
Figure 5.5	LTBP-2 interacts with syndecan-4 but not with syndecan-2	85
Figure 6.1	The distribution of LTBP-2, fibrillin-1, perlecan and laminin in the foetal aorta.....	88
Figure 6.2	Fibrillin-1 and perlecan have potential areas of colocalisation within the medial layer of human foetal aorta.....	91
Figure 6.3	Regions of partial colocalisation of LTBP-2 and perlecan within the medial layer of foetal aorta.....	93
Figure 7.1	Purification of r β ig-h3 aorta.....	98
Figure 7.2	Determination of the extent of coupling of r β ig-h3 or rLTBP-2 to CNBr-activated sepharose.....	98
Figure 7.3	Solubility of BNLPM-1M NaCl following different treatments.....	101
Figure 7.4	BNLPs interacting with sepharose- CL-4B.....	101
Figure 7.5	BNLPs interacting with r β ig-h3-sepharose.....	103
Figure 7.6	Identification of r β ig-h3 in the eluted protein fractions	104
Figure 7.7	Detection of BNLPs binding to r β ig-h3-sepharose using silver staining ..	107
Figure 7.8	Affinity chromatography on columns of r β ig-h3 bound to Ni-sepharose...	110
Figure 7.9	Identification of matrix proteins potentially interacting with LTBP-2	112
Figure 7.10	Effect of decreased concentration of BNLPM on isolating binding ligands for r β ig-h3 and rLTBP-2.....	115
Figure 7.11	Effect of reducing the size of the sepharose affinity columns on non-specific background binding	115
Figure 7.12	2-DGE analysis of BNLPs bound to r β ig-h3 and rLTBP-2	117
Figure 7.13	The effect of a prolonged conditioning step or different solubilisation solution on isoelectric focusing of proteins	120
Figure 7.14	Comparison of the bound proteins to r β ig-h3 and rLTBP-2 using 2-D-DIGE technology	124
Figure 7.15	Repeat of CyDye DIGE fluor minimal labelling of bound proteins to r β ig-h3 and rLTBP-2.....	125

LIST OF TABLES

Table 1.1	Key differences between heparan sulphate and heparin7
Table 1.2	Tissue distribution of type VI collagen using immunofluorescence.15

SUMMARY

Elastic fibres are important components of the extracellular matrices, being composed of an elastin core and fibrillin-microfibrils around the periphery. Elastic fibre formation is a complex developmentally regulated process whereby fibrillin-microfibrils act as templates for the deposition of elastin. Additional matrix macromolecules, including fibulin-4, fibulin-5 and as yet unidentified heparan sulphate proteoglycans (HSPGs), have also been identified as playing important roles in this process.

Fibrillins-1, -2, -3 and latent transforming growth factor- β binding protein (LTBP)-1, -2, -3, -4, associated components of fibrillin-microfibrils, make up a superfamily of extracellular matrix proteins. Fibrillins and LTBPs share a high degree of structural similarity since they both have rod-like structures of tandem EGF-like 6-cysteine repeats interspersed with unique 8-cysteine motifs. LTBP-1, -3 and -4 covalently bind TGF- β and target and store the latent growth factor in the matrix. Unlike the other LTBPs, LTBP-2 does not bind latent TGF- β and its function is poorly understood. LTBP-2 has been shown to bind fibulin-5, an elastin-binding protein and through this interaction it may target tropoelastin-fibulin-5 complexes on to fibrillin-1-microfibrils during elastic fibre assembly. In order to understand more about the role of LTBP-2 in the assembly of elastic fibres and to identify other novel functions, this study involved screening for potential molecular interactions of LTBP-2 with other matrix components, particularly heparin/HSPGs. In elastic tissues HSPGs are found on cell surfaces as syndecans and glypicans and in basement membranes as perlecan.

Full length human recombinant LTBP-2 (rLTBP-2) was expressed in 293 EBNA cells using a modified pCEP-4 vector and purified by nickel affinity chromatography. Upon validation of the purified protein using western blots, solid phase binding assays were used to screen for interaction between rLTBP-2 and heparin. Heparin serves as a useful model for heparan sulphate; due to the lack of adherence of heparin to microtitre plates heparin-BSA conjugate was synthesised and purified for the binding assays. Recombinant LTBP-2 was found to interact with heparin-BSA conjugates using an established solid phase binding assay. The binding was blocked by the addition of heparin (but not chondroitin sulphate) to the liquid phase, confirming the specificity of the interaction. Furthermore, the binding was blocked by the addition of 5mM EDTA and 5mM EGTA, showing that the interaction was cation (calcium) dependent. An apparent K_d of 14.5 ± 3.7 nM was calculated from non-linear regression analysis of the LTBP-2-heparin binding curve, indicating a strong affinity. To identify the location of the heparin binding site(s) on LTBP-2, expression constructs were produced encoding three fragments of LTBP-2, i.e. rLTBP-2NT(H), rLTBP-2C(H) and rLTBP-2CT(H), corresponding to the N-terminal, central and C-terminal regions of the

molecule. Good yields of rLTBP-2C(H) were obtained using the pCEP4-293-EBNA system, and rLTBP-2CT(H) was previously expressed and purified by members of the Gibson laboratory. However, difficulties were encountered with the rLTBP-2NT(H) expression construct and no LTBP-2NT(H) was available during the candidature. The central fragment LTBP-2C(H), (but not the C-terminal fragment LTBP-2CT(H)), was found to bind heparin. However, the apparent K_d of 52.2 ± 6.9 nM was significantly higher than that for full length LTBP-2, indicating that LTBP-2C(H) had relatively lower heparin-binding affinity. This result suggested that an additional heparin binding site(s) is present in the N-terminal region of the molecule.

It was considered that the true tissue ligand(s) for LTBP-2 would be a HSPG rather than heparin. Therefore, LTBP-2 was screened for interaction with HSPGs, recombinant syndecans-2 and -4, and endothelial cell-derived perlecan. Interestingly, LTBP-2 bound strongly to r-syndecan-4 but not r-syndecan-2 even though both molecules were produced in the same mammalian cell system and had been screened for binding to HS-binding growth factor, fibroblast growth factor-2. This finding indicates that LTBP-2 does not interact with all HS and must recognise specific microstructures within the heparan sulphate chains. It appears that syndecan-4 is now a strong candidate as mediator of LTBP-2-cell signalling. LTBP-2 was also found to specifically interact with perlecan in a cation-dependent, heparin-inhibitable manner. Confocal immunohistochemical studies using foetal human aorta showed that LTBP-2 and perlecan generally had distinct distribution patterns within the medial layer, located on fibrillin-microfibrils and basement membranes respectively. However, there were small but widespread regions of LTBP-2-perlecan colocalisation which showed a similar pattern to the fibrillin-1-perlecan colocalisation. Thus it would appear that LTBP-2 is present at microfibril-basement membrane interfaces and may be involved in stabilising the interaction between these two structural elements of the matrix. This concept needs to be confirmed at the ultrastructural level. The interaction of LTBP-2 with perlecan during embryonic development is also worthy of investigation.

In parallel studies, a proteomic approach was used to identify other matrix binding proteins for LTBP-2. This was carried out in parallel with another matrix protein of poorly defined function, transforming growth factor-beta-inducible gene-h3 (β ig-h3). Recombinant LTBP-2 and β ig-h3 coupled to sepharose were used as bait proteins to screen complex mixtures of matrix proteins from the elastic tissue nuchal ligament and basement membrane preparation Matrigel. Initial studies showed that non-specific background binding to these proteins was a major problem. In efforts to overcome this difficulty, binding conditions were varied with limited success. A two-dimensional gel approach was used to fractionate and compare proteins binding to LTBP-2 with those binding to β ig-h3. The differentially-

displayed protein spots were to be identified by mass spectrometry. However, complications in comparing the patterns on two separate gels made identification of candidate spots challenging. Finally, CyDye DIGE fluor dyes were used to fractionate proteins binding to LTBP-2 and β ig-h3 on the same gel, but unfortunately this work could not be completed in the time frame of the candidature.